-
Mashup Score: 24
Long-term survival (LTS) in multiple myeloma (MM), defined as survival of ≥10 years post-diagnosis following a single line of therapy, is an increasingly o
Source: ashpublications.orgCategories: General Medicine NewsTweet
-
Mashup Score: 1UPDATED INTERIM RESULTS OF SONROTOCLAX + DEXAMETHASONE IN PATIENTS... by Binod Dhakal - 2 month(s) ago
EHA Library; Dhakal B. Jun 13 2025; 4160128;
Source: library.ehaweb.orgCategories: General Medicine NewsTweet-
EHA Library - The official digital education library of European Hematology Association (EHA)! Highly impressive activity of this novel bcl2 inhibitor in MM; excited to present poster at EHA and oral@at Lugano @MCWCancerCenter https://t.co/CsYNeohX4n
-
-
Mashup Score: 8Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma - 6 month(s) ago
Background Polyclonal autologous T cells that are epigenetically reprogrammed through mTOR inhibition and IFN-α polarization (RAPA-201) represent a novel approach to the adoptive T cell therapy of cancer. Ex vivo inhibition of mTOR results causes a shift towards T central memory (TCM) whereas ex vivo IFN-α promotes type I cytokines, with each of these functions known to enhance the adoptive T cell therapy of cancer. Rapamycin-resistant T cells polarized for a type II cytokine phenotype were previously evaluated in the allogeneic transplantation context. Methods The clinical trial ([NCT04176380][1]) evaluated RAPA-201 therapy in combination with fludarabine-sparing low-dose host conditioning for the treatment of patients with relapsed, refractory multiple myeloma (RRMM). Results From December 2020 to December 2022, 14 patients with RRMM received a median of three RAPA-201 infusions (median dose, 80×106 cells). RAPA-201 drug products (DPs) were: polyclonal; enriched for TCM cells; reduce
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet-
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma | Journal for ImmunoTherapy of Cancer @MCWCancerCenter @Chhabra_mayo @Phari https://t.co/b7PUaeJEL2
-
-
Mashup Score: 15Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1-3 Prior Lines: SEER-Medicare Database - 6 month(s) ago
Lenalidomide, an immunomodulatory drug (IMiD), is considered a key component of standard of care for the treatment of patients with multiple myeloma (MM).1 The National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) guidelines recommend lenalidomide-based triplet regimens (eg, carfilzomib-lenalidomide-dexamethasone, daratumumab-lenalidomide-dexamethasone, bortezomib-lenalidomide-dexamethasone, and ixazomib-lenalidomide-dexamethasone) for the initial treatment of patients with MM, including transplant-eligible and -ineligible patients.
Categories: General Medicine News, Hem/OncsTweet-
Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1-3 Prior Lines: SEER-Medicare Database - Clinical Lymphoma, Myeloma and Leukemia https://t.co/T1bJcpmdQ9
-
-
Mashup Score: 1Autologous Transplantation for Newly Diagnosed Multiple Myeloma - 7 month(s) ago
This systematic review and meta-analysis reviews phase 3 randomized clinical trials of high-dose therapy followed by autologous stem cell transplant in patients with multiple myeloma.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
@VincentRK @AlGarfall For the triplet induction/ASCT, we argued here the potential reasons for not seeing OS! https://t.co/7htw4DYXJk
-
-
Mashup Score: 0
Background: Cytokine release triggered by a hyperactive immune response is thought to contribute to severe acute respiratory syndrome coronavirus 2019 (SARS-…
Source: www.frontiersin.orgCategories: General Medicine News, Hem/OncsTweet-
https://t.co/1vRUr9vXwX
-
-
Mashup Score: 13
Lenalidomide-refractory patients treated with 1–3 prior LOT have poor PFS and OS, which generally worsen with each additional LOT, highlighting the need for new and effective treatments for this population.
Source: www.ejcancer.comCategories: General Medicine News, Hem/OncsTweet-
Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: analysis of individual patient-level data from daratumumab clinical trials - European Journal of Cancer https://t.co/wFEfZYPPcS
-
-
Mashup Score: 5
Program: Oral and Poster Abstracts Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III Hematology Disease Topics & Pathways: Research, Clinical trials, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Plasma Cell Disorders, Clinical Research, Diseases, Biological therapies, Treatment Considerations, Lymphoid Malignancies, Human, Study Population Chengcheng Fu 1 *, Lingzhi Yan 1 *, Weiqin Yao 1 *, Jingjing Shang 1 *, Song Jin 1 *, Shuang Yan 1 *, Fang Tang 1 *,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Paper: A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma https://t.co/qjxJx0kXQi
-
-
Mashup Score: 13Paper: MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial - 8 month(s) ago
Program: Oral and Poster Abstracts Session: 654. Multiple Myeloma: Pharmacologic Therapies: Poster I Hematology Disease Topics & Pathways: Research, Clinical trials, Clinical Research Binod Dhakal, MBBS 1, Rebecca Silbermann 2,3, Timothy M Schmidt, MD 4, Eva Medvedova, MD 2 *, Susan Bal, MD 5 *, Smith Giri 5 *, Naresh Bumma, MD 6, Abdullah Mohammad Khan, MD, MBBS 7, Andrew J. Cowan, MD 8 *, Rajshekhar Chakraborty, MD 9, Gayathri Ravi, MD 10, Kelly Godby 5 *, Bhagirathbhai R. Dholaria, MBBS 11, Muhamed
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
@End_myeloma @RahulBanerjeeMD @MMBaljevicMD @nsc_natalie @ldandersonjr @schadeh @rajshekharucms @SusanBal9 @SarahCannonDocs One of the most innovative trials in NDMM by the brilliant @End_myeloma and our dear friends from the COMMIT team! https://t.co/rj0JXQB1FK
-
-
Mashup Score: 1Paper: Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma - 8 month(s) ago
Program: Oral and Poster Abstracts Session: 653. Multiple Myeloma: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, Translational Research Binod Dhakal, MBBS 1, Michael Slade, MD, MS 2, Ravi Narra, MD 3 *, Mostafa E. Mohamed 4 *, Othman S Akhtar, MD 1, Hima Bansal, PhD 5 *, Maria Jose Acevedo-Calado, PhD 5 *, Oren Pasvolsky, MD 6 *, Mahmoud R. Gaballa, MD 5, Melody R. Becnel, MD 7, Donna M. Weber, MD 5, Krina K. Patel, MD, MSc 8, Sheeba K. Thomas, MD 7, J Christine
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
CMMCs kinetics in MM treated with bispecific antibodies @MCWCancerCenter @MDAndersonNews https://t.co/nNMPM2hi6r
-
Molecular and Immunological Determinants of Long-Term Survival in Multiple Myeloma | Blood Advances | American Society of Hematology @MedicalCollege @MCWCancerCenter https://t.co/YxWui4ZCUA